Mechanistic Toxicology

The editors and readers of the journal Molecular Carcinogenesis could argue that the shift to mechanistic toxicology proposed in Marcia Clemmitt's recent article in The Scientist (Feb. 17, 1992, page 1) has already occurred. For the past five years, Molecular Carcinogenesis has been reporting the growth of, and changes in, all fields of carcinogenesis, including toxicology. The need for a journal that emphasized the causative mechanisms of cancer at the molecular level became apparent in 1987

Written byThomas Slaga
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

The need for a journal that emphasized the causative mechanisms of cancer at the molecular level became apparent in 1987, when the burgeoning field of molecular biology made it possible to examine carcinogenesis at a more intimate level. In conjunction with the University of Texas M.D. Anderson Cancer Center and Wiley-Liss Inc. of New York, we started Molecular Carcinogenesis as a peer-reviewed forum for work on the molecular mechanisms of carcinogenesis.

Advances in molecular biology have enabled us to move from what University of Maryland pathology professor Ellen Silbergeld referred to in the article as "hitting an animal over the head and seeing which organ falls out first" to determining the precise physical interactions between carcinogens and the DNA and proteins of target cells.

For example, in a recent issue of Molecular Carcinogenesis (4:176-9, 1991), C. Anita H. Bigger of the National Cancer Institute and associates reported that the anti ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies